Search

Your search keyword '"Milhem M"' showing total 27 results

Search Constraints

Start Over You searched for: Author "Milhem M" Remove constraint Author: "Milhem M" Database Unpaywall Remove constraint Database: Unpaywall
27 results on '"Milhem M"'

Search Results

1. 845P Vidutolimod + pembrolizumab as 2L+ treatment in patients with anti–PD-1–refractory melanoma and adrenal insufficiency: Subgroup analyses of a phase Ib study

3. Safety and Efficacy of RP1 + Nivolumab in Patients with Non-Melanoma Skin Cancer of the Head and Neck: Results From IGNYTE Phase 1/2 Multi-Cohort Clinical Trial

4. A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft tissue sarcomas who are not candidates for chemotherapy

5. Talimogene laherparepvec (T-VEC) in combination (combo) with ipilimumab (ipi) versus ipi alone for advanced melanoma: 3-year landmark analysis of a randomized, open-label, phase II trial

7. Results of phase I clinical trial of high doses of seleno-l-methionine (SLM) in sequential combination with axitinib in previously treated and relapsed clear cell renal carcinoma (ccRCC) patients

9. PB1737 MULTICENTER, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE BIOEQUIVALENCE AND FOOD EFFECT ON THE BIOAVAILABILITY OF CC-486 (ORAL AZACITIDINE) TABLETS IN ADULT CANCER PATIENTS

11. Phase Ib/II study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who had progressive disease on or after prior anti-PD-1 therapy

12. Phase Ib/II, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy

14. Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma

15. Five-year efficacy and safety update from METRIC: Trametinib vs chemotherapy in patients with BRAF V600E/K–mutant advanced or metastatic melanoma

16. A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas

17. Interim safety and efficacy of a randomized (1:1), open-label phase 2 study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected, stage IIIB-IV melanoma

18. Efficacy and safety of trabectedin or dacarbazine for the treatment of patients with uterine leiomyosarcoma after prior chemotherapy: A subgroup analysis of the randomized phase 3 SAR-3007 study

20. 1321 Efficacy and safety of trabectedin (T) or dacarbazine (D) in an elderly patient subgroup (65 years) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS) after prior chemotherapy

21. A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: The TRUSTS trial

22. A Phase 1B/2, Multicenter, Open Label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec (T-Vec) and Ipilimumab (Ipi) Versus Ipi Alone in Previously Untreated, Unresected, Stage Iiib, Iiic, and Iv Melanoma

23. Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study

24. Efficacité du trametinib (T), sur la survie sans progression (SSP) et la survie globale (SG), en comparaison à la chimiothérapie (C) chez des patients (pts) ayant un mélanome métastatique (MM) avec mutation de BRAFV600E/K

Catalog

Books, media, physical & digital resources